Siemens Healthineers AG (DE000SHL1006)
 
 

46,92 EUR

Stand (close): 01.07.25

Nachrichten

Datum / Uhrzeit Titel Bewertung
26.06.25 13:07:00 Europe Electrophysiology Market Research Report 2024-2025 & 2034, Competitive Analysis of Koninklijke Philips, Siemens Healthineers, Volta Medical
Company Logo

The Europe electrophysiology market is poised for substantial growth, projected to leap from $2.49 billion in 2024 to $7.64 billion by 2034, supported by a CAGR of 11.85%. This expansion is fueled by the increasing prevalence of cardiovascular disorders, advancements in electrophysiology technologies like 3D cardiac mapping, and the rising demand for minimally invasive procedures due to an ageing population. While challenges such as high equipment costs and regulatory complexities exist, strategic collaborations and enhanced healthcare infrastructure are driving market growth. Key players, including Siemens Healthineers AG, Biotronik, and Philips, are at the forefront.

European Electrophysiology MarketEuropean Electrophysiology Market

Dublin, June 26, 2025 (GLOBE NEWSWIRE) -- The "Europe Electrophysiology Market: Analysis and Forecast, 2024-2034" report has been added to ResearchAndMarkets.com's offering.

The Europe electrophysiology market is projected to reach $7.64 billion by 2034 from $2.49 billion in 2024, growing at a CAGR of 11.85% during the forecast period 2024-2034. The rising prevalence of cardiovascular disorders, particularly arrhythmias, and the quick development of new technologies such as 3D cardiac mapping, catheter ablation platforms, and sophisticated diagnostic systems are driving the market for electrophysiology devices in Europe.

The need for minimally invasive procedures is increasing due to an ageing population at higher risk of heart diseases; catheter-based ablations are preferred because of their lowered procedural risks and quicker recovery. Increased public awareness of heart health, ongoing improvements to the European healthcare system, and focused investments from public and commercial entities are all contributing to the market's rapid expansion.

Market Introduction

The growing incidence of arrhythmias, especially atrial fibrillation, and the growing need for minimally invasive cardiac procedures are driving the electrophysiology (EP) industry in Europe. Due to the increased prevalence of heart rhythm abnormalities brought on by Europe's ageing population, early diagnosis and efficient treatment are becoming more and more important from a clinical and financial standpoint. The way electrophysiologists identify, locate, and treat aberrant electrical activity in the heart is being revolutionised by advanced technology like 3D cardiac mapping systems, radiofrequency and cryoablation catheters, and AI-enabled navigation platforms.

Digital technologies that combine imaging, mapping, and robotic catheter control, as well as contemporary EP labs and hybrid operating suites, are being invested in by European healthcare systems, particularly those in the Western and Nordic areas. Favourable reimbursement conditions are pushing hospitals to improve infrastructure and increase service offerings, especially for atrial fibrillation ablation. In the meantime, patient care paradigms are changing due to the desire for wearable cardiac monitoring and outpatient operations.

But there are still difficulties. Adoption is nevertheless hampered by high equipment prices, a shortage of qualified electrophysiologists, and disparities in reimbursement between EU nations. Manufacturers are further complicated by regulatory compliance under the EU Medical Device Regulation. Nonetheless, Europe's EP industry is well-positioned for sustained growth due to robust clinical need and innovation pace.

Story Continues

How can this report add value to an organization?

Growth/Marketing Strategy: The partnership, alliance, and business expansion accounted for the maximum number of key developments in the Europe electrophysiology market between January 2022 and December 2024.

Competitive Strategy: The Europe electrophysiology market has numerous established players with product and service portfolios. Key players in the Europe electrophysiology market analyzed and profiled in the study involve established players offering electrophysiology products and services.

Europe Electrophysiology Market Trends, Drivers and Challenges

Trends

Adoption of high-resolution 3D and ultra-high-density cardiac mapping systems Integration of AI and machine learning for automated arrhythmia substrate identification Growth of remote and robotic catheter navigation platforms Emergence of combined EP-imaging suites (MRI/CT overlay with mapping) Expansion of wearable and implantable monitoring devices for continuous rhythm surveillance

Drivers

Increasing prevalence of atrial fibrillation and other arrhythmias in Europe's aging population Strong clinical evidence favoring minimally invasive catheter-ablation procedures Reimbursement support across Western Europe for advanced EP interventions Collaboration between device makers, hospitals and research institutes accelerating innovation Heightened patient and physician demand for safer, more effective heart-rhythm therapies

Challenges

High capital and maintenance costs for state-of-the-art EP labs and equipment Fragmented reimbursement frameworks and variable hospital budgets across EU member states Need for specialized training and scarcity of experienced electrophysiologists Regulatory complexity and lengthy approval pathways for novel EP technologies Data-integration and interoperability hurdles between legacy hospital IT systems and new EP platforms

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, type portfolio, and market penetration.

Some prominent names in the Europe electrophysiology market include:

Koninklijke Philips N.V. Siemens Healthineers AG Volta Medical CathVision ApS Biotronik

Key Attributes:

Report Attribute Details No. of Pages 65 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $2.49 Billion Forecasted Market Value (USD) by 2034 $7.64 Billion Compound Annual Growth Rate 11.8% Regions Covered Europe

Key Topics Covered:

Executive Summary

Scope and Definition

1 Market: Industry Outlook
1.1 Industry Outlook
1.1.1 Supply Chain Overview
1.1.1.1 Risks within the Supply Chain
1.1.2 Reimbursement Scenario
1.1.2.1 Overview
1.1.2.2 Europe
1.1.3 Value Chain Analysis
1.1.3.1 Overview
1.1.3.2 Stakeholders at Each Stage of the Value Chain
1.1.3.3 Strategic Partnerships, Mergers, and Acquisitions in the Value Chain
1.2 Trends: Current and Future Impact Assessment
1.2.1 Increasing Adoption of Advanced 3D Mapping Systems and Real-Time Imaging
1.2.2 Emerging Use of Artificial Intelligence in Predictive Modelling and Personalized Treatment
1.3 Patent Analysis
1.3.1 Patent Filing Trend (by Country, Year)
1.4 Regulatory Framework
1.4.1 European Union (EU)
1.4.2 U.K.
1.4.3 France
1.4.4 Germany
1.4.5 Italy
1.4.6 Spain
1.5 Market Dynamics Overview
1.5.1 Market Drivers
1.5.1.1 Innovative Technological Developments
1.5.1.2 Proliferation of New Entrants and Its Market Implications
1.5.1.3 Expanding Investments, Funding, and Grant Support for Cardiac Surgery and Electrophysiology
1.5.1.4 Increasing Disease Incidence and Procedural Volume
1.5.2 Market Restraints
1.5.2.1 High Product Costs and Inadequate Reimbursement Policies
1.5.2.2 Increasing Device Reuse and Reprocessing Trends
1.5.3 Market Opportunities
1.5.3.1 Expansion of Emerging Markets
1.5.3.2 Next-Generation Ablation Technologies

2 Electrophysiology Market (by Region), $Million, 2022-2034
2.1 Regional Summary
2.2 Europe
2.2.1 Regional Overview
2.2.2 Driving Factors for Market Growth
2.2.3 Factors Challenging the Market
2.2.4 France
2.2.5 Italy
2.2.6 Germany
2.2.7 U.K.
2.2.8 Spain
2.2.9 Rest-of-Europe

3 Markets - Competitive Benchmarking & Company Profiles
3.1 Electrophysiology Market: Competitive Landscape
3.1.1 Corporate Strategies, January 2019-December 2024
3.1.2 Strategic Initiatives (by Year), January 2019-December 2024
3.1.3 Partnerships, Alliances, and Business Expansions
3.1.4 New Offerings
3.1.5 Regulatory Approval
3.1.6 Funding Activities
3.1.7 Merger and Acquisition
3.1.8 Key Developments and Milestones, 2015-2023
3.2 Company Profiles
3.2.1 Overview
3.2.2 Top Products
3.2.3 Top Competitors
3.2.4 Target Customers
3.2.5 Analyst View

4 Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/hzl13u

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

European Electrophysiology Market

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

View Comments
26.06.25 09:00:00 Icon Group and Varian Expand Global Partnership to Deliver Advanced Cancer Technology Across the UK
LONDON, June 26, 2025--(BUSINESS WIRE)--Icon Group, a global leader in integrated cancer care, has announced a significant new agreement with Varian, a Siemens Healthineers company, involving an investment of more than USD $18.7 million to expand access to cutting-edge, world-class cancer treatment technology across the United Kingdom.

The agreement includes the rollout of Varian’s advanced TrueBeam linear accelerators, along with next-generation imaging and software platforms such as RapidArc Dynamic (RAD), HyperSight, IDENTIFY, and a continued pipeline of new technology, designed to deliver faster, highly precise, patient-centred care.

This investment reinforces Icon’s ongoing commitment to increasing access to world-class, precision-led cancer care and marks the first installation of this full suite of comprehensive Varian hardware and software in the UK. The technology will be rolled out across Icon Cancer Centre London and three new locations in Brighton, Warwickshire, and Derby, with further installations planned to support Icon’s growing footprint in the region.

Icon Europe CEO, Aldo Rolfo said this technology will increase access to world-class care.

"At Icon, we’re market leaders in introducing the absolute latest in radiotherapy technologies and treatments and ensuring we increase access to world-class care to communities we serve," said Aldo.

"This large investment with Varian enables us to continue leading in precision cancer care and improving access to treatment and better outcomes for patients across the UK."

Enhancing patient experience and outcomes

The new agreement will introduce Varian’s most innovative technologies to UK patients, delivering faster treatment times, more precise imaging and delivery, and streamlined workflows that aim to improve the overall treatment experience:

TrueBeam – an advanced linear accelerator (radiation therapy treatment machine) designed to deliver high-speed, image-guided radiation therapy for a wide range of cancers. RapidArc Dynamic (RAD) – a state-of-the-art planning and delivery platform that reduces treatment planning time by up to 70% while enhancing plan quality and reducing dose exposure to critical organs. HyperSight – advanced cone-beam CT imaging delivering clearer, faster images, that enhance anatomical visualisation and support more precise treatment delivery, while also helping streamline workflows by reducing image acquisition time. IDENTIFY – real-time surface-guided radiotherapy (SGRT) that increases treatment accuracy and can significantly reduce, and in many cases eliminate, the need for permanents tattoo markings, a sometime unfriendly reminder of a patient’s diagnosis.

Story Continues

The first installations will take place at Icon Cancer Centre London, with other sites following later in 2026.

Icon Group’s UK Chief Medical Officer, Dr Penny Kechagioglou said this new technology is a game-changer.

"This technology marks a new benchmark for radiotherapy in the UK," said Dr Kechagioglou.

"There is currently an underutilisation of radiotherapy treatment, with fewer than 30% of cancer patients receiving it, less than the global recommended rate of 40 – 50% of cancer diagnosis1.

"This is a real win for cancer patients who will benefit from timely access to highly advanced non-invasive radiotherapy designed to improve both patient experience and outcomes."

Head of Varian Europe, Middle East and Africa, Virve Sarja is looking forward to rolling out this technology.

"We’re proud to strengthen our collaboration with Icon in the UK," said Virve.

"This partnership reflects a shared commitment to expanding access to cutting edge radiotherapy technologies in the region and redefining what’s possible in cancer treatment. By combining innovation with a strong focus on patient care, we’re helping to raise the standard of treatment and move closer to a world without fear of cancer."

© 2025 VARIAN MEDICAL SYSTEMS, INC. All trademarks are the property of their respective owners.

References

1Cancer Research UK https://news.cancerresearchuk.org/2025/03/13/cancer-waiting-times-latest-updates-and-analysis/

About Icon Group

Icon Group is a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom.

Icon is built on a strong but simple mission - to deliver the best care possible to as many people as possible, as close to home as possible. The group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research, theranostics, pharmacy and compounding to deliver a truly integrated, end-to-end seamless service for cancer patients. With more than 3,500 team members, a network of more than 350 doctors, over 55 cancer centres, six compounding facilities and operational support of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.

For more information visit http://www.icongroup.global and follow Icon Group on LinkedIn at https://www.linkedin.com/company/icon-group

About Varian

At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our perspective while also pursuing clinical research to create a more efficient, and more personalized care pathway. Because, for cancer patients everywhere, their fight is our fight. For more information, visit http://www.varian.com.

Icon and Varian’s global partnership

Icon Group and Varian have a long history of collaboration in delivering advanced cancer care across Australia, New Zealand, Asia, and now the UK. Icon clinicians and medical professionals are active members of Varian’s global AI and RapidArc Dynamic consortiums and are engaged in clinical research and product development initiatives worldwide.

The expanded partnership in the UK also builds on a five-year professional services and research agreement between Icon and Varian established in 2022 and highlights a shared commitment to innovation, access, and improved patient outcomes.

QR700024577

View source version on businesswire.com: https://www.businesswire.com/news/home/20250626798284/en/

Contacts

Media Contacts Icon Group
media@icon.team

Varian
Kristin Corey
Varian Corporate Communications
Kristin.Corey@varian.com

View Comments
20.06.25 15:37:00 Medical Imaging Equipment Market Size to Hit USD 62.51 Billion by 2031 with 4.5% CAGR | Business Market Insights
NEW YORK, June 20, 2025 /PRNewswire/ -- Players such as GE HealthCare, Siemens Healthineers, Philips, and Canon Medical are investing in R&D, expanding product portfolios, and teaming up to stay ahead. These steps, along with helpful government rules and better healthcare systems worldwide, will keep pushing the market forward in the years to come.Business Market Insights Logo

The research report "Medical Imaging Equipment Market Size and Forecast (2021–2031)" forecasts how the market is set to surge 35.94% by 2031 as technological advancements reshapes global medical imaging equipment ecosystems. The report spotlights that the integration of artificial intelligence (AI) and machine learning (ML) into imaging systems has further revolutionized the field.

To explore the valuable insights in the Medical Imaging Equipment Market report, you can easily download a sample PDF of the report - https://www.businessmarketinsights.com/sample/BMIPUB00031626/

Technology is starting to become a major driver for this market. We expect integrated capabilities of medical imaging with AI-powered technologies such as smart automated diagnostics, enhanced image analysis, and real-time decision support to improve clinical workflows with higher accuracy, efficiency and expand access to high quality care. This represents a fundamental change in the way medical imaging supports formal diagnosis and treatment worldwide.

Overview of report findings

Market Growth
The Medical Imaging Equipment Market is projected to grow from US$ 45,983.21 million in 2024 to US$ 62,509.98 million by 2031, registering a compound annual growth rate (CAGR) of 4.5% between 2025 and 2031.

Rising prevalence of chronic and complex disease, increasing Integration with artificial intelligence, increasing government initiatives, and regulatory approval are key factors propelling market growth. On the other hand, increasing product recall and high cost of advance medical imaging equipment are hindering the market expansion. Favorable Government Initiatives and Funding
Globally, the amount of funding for health infrastructure is increasing. Government across the globe is launching several screening programs for diagnosis of life-threatening diseases. In addition, governments are providing subsidies or grants to expand the diagnostic capacity of imaging systems. Public health initiatives aimed at early disease detection, especially for cancer and cardiovascular conditions, are increasing the demand for advanced imaging technologies. Additionally, regulatory support for faster approval of innovative devices and investments in digital health ecosystems are accelerating market growth. Most of these initiatives not only improve access to imaging services, but they allow manufacturers opportunities for expanding their existing product offering in both developed and emerging markets. Increasing Demand for Early and Accurate Diagnosis Rising demand for early and precise diagnosis is significantly fuelling the medical imaging equipment market. Early detection of diseases like cancer, cardiovascular disease, and neurological disorders enhances treatment outcomes and decreases healthcare expenditure. Sophisticated imaging technologies allow doctors to detect abnormalities at early stages with high accuracy, facilitating timely intervention. With increased awareness among patients and medical professionals regarding the advantages of early diagnosis, the need for advanced imaging machines that provide accurate and precise results is growing consistently, boosting market growth worldwide. Geographic Insights North America continues to be the top region for medical imaging equipment due to an increasing rate of chronic diseases, demand for early and accurate diagnoses, and technological advancements. The US and Canada fuel growth with major healthcare providers and technology innovators investing heavily in advanced imaging solutions such as AI-powered systems and portable devices. Although imaging innovations such as hybrid imaging and cloud-based imaging improvements provide a significant increase in speed, accuracy, and overall diagnostic capabilities, it is important to deploy these innovations in a cost-effective manner to healthcare facilities experiencing higher demand for quality care.

Story Continues

Europe, has a well-established healthcare infrastructure providing a foothold for imaging technology and equipment, including low-radiation devices, hybrid imaging technologies, and other advanced imaging modalities. An increased focus on personalized medicine and sustainable healthcare solutions will also contribute to advancing the regional market.

For Detailed Medical Imaging Equipment Market Insights, Visit: https://www.businessmarketinsights.com/reports/medical-imaging-equipment-market

Market Segmentation

Based on Product Type, the market is segmented into Magnetic Resonance Imaging Systems, Ultrasound, Computed Tomography Devices, X-Ray Imaging Devices and Nuclear Imaging Systems. The Computed Tomography Devices segmented dominated the market in 2024. Based on Application, the market is segmented into Cardiology, Oncology, Neurology, Orthopedics, Gastroenterology, Gynecology, Urology and Others. The Oncology segment dominated the market in 2024. Based on End User, the market is segmented into Hospitals, Specialty Clinics, Diagnostics Imaging Centers, Academic & Research Institutes, and Others. The Hospitals segment dominated the market in 2024.

Stay Updated on The Latest Medical Imaging Equipment Market Trends: https://www.businessmarketinsights.com/sample/BMIPUB00031626/

Competitive Strategy & Development

- Key Players: The Medical Imaging Equipment Market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

GE HealthCare Siemens Healthineers AG FUJIFILM Holdings Corporation CANON MEDICAL SYSTEMS CORPORATION Koninklijke Philips N.V. Shimadzu Corporation Hologic, Inc. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

- Trending Topics: In-Situ Hybridization (FISH) Imaging, Clinical Trial Imaging, Whole Slide Imaging, Diagnostic Imaging, Retinal Imaging

Purchase Premium Copy of Global Medical Imaging Equipment Market Size and Growth Report (2025-2031) at:  https://www.businessmarketinsights.com/buy/BMIPUB00031626/

Global Headlines

"India's first indigenous MRI scanner, set for clinical trials at AIIMS- India has developed its first indigenous MRI scanner, which will be installed at AIIMS-Delhi by October 2025. The initiative aims to cut MRI costs by 50 per cent and reduce reliance on imports while increasing public access to medical imaging." "Radon Medical Announces Acquisition of Alpha Imaging– In November 2024, Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, announced it has acquired Alpha Imaging, one of the largest distributors and servicers of medical imaging equipment in the eastern region of the U.S.

Conclusion

The medical imaging equipment market is poised for steady growth. This growth is driven by rising chronic diseases, a higher need for early and accurate diagnoses, and quick tech progress like AI and portable imaging. New trends such as the shift toward the tailored or personalized medicine and hybrid imaging systems, are driving new ideas. On the other hand, factors such as high cost of advance imaging modalities and stringent regulatory guidelines can hamper the industry growth.

More Related Global Research Reports - https://www.businessmarketinsights.com/reportstore

Trending Related Reports:

The North America medical imaging equipment services market is expected to reach US$ 8,916.28 Mn in 2027 from US$ 6,526.03 Mn in 2018. The market is estimated to grow with a CAGR of 3.6% from 2019-2027.

The US medical imaging equipment services market is expected to reach US$ 5,848.2 Mn in 2027 from US$ 4,169.0 Mn in 2018. The market is estimated to grow with a CAGR of 3.9% from 2019-2027.

Medical imaging market in Europe is expected to grow from US$ 7,703.9 million in 2021 to US$ 10,003.1 million by 2028; it is estimated to grow at a CAGR of 3.8% from 2021 to 2028.

The medical endoscopes market size is expected to reach US$ 22,467.07 million by 2031 from US$ 14,487.23 million in 2024. The market is estimated to record a CAGR of 6.5% from 2025 to 2031.

About Us:

At Business Market Insights, we offer a subscription-based platform and syndicated market research services, granting access to an extensive library of industry and company reports. With expertise in sectors such as Electronics & Semiconductor, Aerospace & Defense, Healthcare and others, we help businesses gain a competitive edge in dynamic markets.

Contact Us: If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
E-mail: ankit.mathur@businessmarketinsights.com
Phone: +1-646-491-9876
Home - https://www.businessmarketinsights.com/

Logo - https://mma.prnewswire.com/media/2715706/BMI_Logo.jpgCision

View original content to download multimedia:https://www.prnewswire.com/news-releases/medical-imaging-equipment-market-size-to-hit-usd-62-51-billion-by-2031-with-4-5-cagr--business-market-insights-302487228.html

SOURCE Business Market Insights

View Comments
15.04.25 10:46:37 Siemens Healthineers AG's (ETR:SHL) top owners are public companies with 62% stake, while 16% is held by individual investors
Key Insights

Siemens Healthineers' significant public companies ownership suggests that the key decisions are influenced by shareholders from the larger public Siemens Aktiengesellschaft owns 62% of the company Institutions own 11% of Siemens Healthineers

We've discovered 1 warning sign about Siemens Healthineers. View them for free.

Every investor in Siemens Healthineers AG (ETR:SHL) should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are public companies with 62% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

Individual investors, on the other hand, account for 16% of the company's stockholders.

In the chart below, we zoom in on the different ownership groups of Siemens Healthineers.

View our latest analysis for Siemens Healthineers XTRA:SHL Ownership Breakdown April 15th 2025

What Does The Institutional Ownership Tell Us About Siemens Healthineers?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Siemens Healthineers already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Siemens Healthineers, (below). Of course, keep in mind that there are other factors to consider, too.XTRA:SHL Earnings and Revenue Growth April 15th 2025

Siemens Healthineers is not owned by hedge funds. Our data shows that Siemens Aktiengesellschaft is the largest shareholder with 62% of shares outstanding. This essentially means that they have extensive influence, if not outright control, over the future of the corporation. Siemens Beteiligungsverwaltung GmbH & Co. OHG is the second largest shareholder owning 12% of common stock, and The Vanguard Group, Inc. holds about 1.1% of the company stock.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Story Continues

Insider Ownership Of Siemens Healthineers

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our data cannot confirm that board members are holding shares personally. It is unusual not to have at least some personal holdings by board members, so our data might be flawed. A good next step would be to check how much the CEO is paid.

General Public Ownership

The general public, who are usually individual investors, hold a 16% stake in Siemens Healthineers. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Company Ownership

It seems that Private Companies own 12%, of the Siemens Healthineers stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Public Company Ownership

Public companies currently own 62% of Siemens Healthineers stock. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

It's always worth thinking about the different groups who own shares in a company. But to understand Siemens Healthineers better, we need to consider many other factors. For example, we've discovered 1 warning sign for Siemens Healthineers that you should be aware of before investing here.

Ultimately the future is most important. You can access this freereport on analyst forecasts for the company.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments
26.03.25 04:00:05 Siemens Healthineers' (ETR:SHL) investors will be pleased with their favorable 57% return over the last five years
If you buy and hold a stock for many years, you'd hope to be making a profit. Furthermore, you'd generally like to see the share price rise faster than the market. But Siemens Healthineers AG (ETR:SHL) has fallen short of that second goal, with a share price rise of 44% over five years, which is below the market return. Unfortunately the share price is down 6.1% in the last year.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

During five years of share price growth, Siemens Healthineers achieved compound earnings per share (EPS) growth of 3.0% per year. This EPS growth is slower than the share price growth of 8% per year, over the same period. This suggests that market participants hold the company in higher regard, these days. That's not necessarily surprising considering the five-year track record of earnings growth.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).XTRA:SHL Earnings Per Share Growth March 26th 2025

We know that Siemens Healthineers has improved its bottom line lately, but is it going to grow revenue? Check if analysts think Siemens Healthineers will grow revenue in the future.

What About Dividends?

It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. In the case of Siemens Healthineers, it has a TSR of 57% for the last 5 years. That exceeds its share price return that we previously mentioned. The dividends paid by the company have thusly boosted the total shareholder return.

A Different Perspective

Investors in Siemens Healthineers had a tough year, with a total loss of 2.7% (including dividends), against a market gain of about 16%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. On the bright side, long term shareholders have made money, with a gain of 9% per year over half a decade. It could be that the recent sell-off is an opportunity, so it may be worth checking the fundamental data for signs of a long term growth trend. It's always interesting to track share price performance over the longer term. But to understand Siemens Healthineers better, we need to consider many other factors. For instance, we've identified 1 warning sign for Siemens Healthineers that you should be aware of.

Story Continues

If you are like me, then you will not want to miss this freelist of undervalued small caps that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on German exchanges.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments
03.03.25 08:10:05 Is Siemens Healthineers AG's (ETR:SHL) Latest Stock Performance Being Led By Its Strong Fundamentals?
Siemens Healthineers' (ETR:SHL) stock up by 4.0% over the past three months. Given its impressive performance, we decided to study the company's key financial indicators as a company's long-term fundamentals usually dictate market outcomes. Particularly, we will be paying attention to Siemens Healthineers' ROE today.

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. Simply put, it is used to assess the profitability of a company in relation to its equity capital.

Check out our latest analysis for Siemens Healthineers

How To Calculate Return On Equity?

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Siemens Healthineers is:

10% = €2.0b ÷ €20b (Based on the trailing twelve months to December 2024).

The 'return' is the income the business earned over the last year. Another way to think of that is that for every €1 worth of equity, the company was able to earn €0.10 in profit.

What Has ROE Got To Do With Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

A Side By Side comparison of Siemens Healthineers' Earnings Growth And 10% ROE

At first glance, Siemens Healthineers seems to have a decent ROE. Further, the company's ROE compares quite favorably to the industry average of 8.0%. Despite this, Siemens Healthineers' five year net income growth was quite low averaging at only 4.0%. This is generally not the case as when a company has a high rate of return it should usually also have a high earnings growth rate. We reckon that a low growth, when returns are quite high could be the result of certain circumstances like low earnings retention or poor allocation of capital.

Next, on comparing with the industry net income growth, we found that the growth figure reported by Siemens Healthineers compares quite favourably to the industry average, which shows a decline of 2.3% over the last few years.XTRA:SHL Past Earnings Growth March 3rd 2025

Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Has the market priced in the future outlook for SHL? You can find out in our latest intrinsic value infographic research report.

Story Continues

Is Siemens Healthineers Using Its Retained Earnings Effectively?

Siemens Healthineers has a three-year median payout ratio of 55% (implying that it keeps only 45% of its profits), meaning that it pays out most of its profits to shareholders as dividends, and as a result, the company has seen low earnings growth.

Additionally, Siemens Healthineers has paid dividends over a period of six years, which means that the company's management is determined to pay dividends even if it means little to no earnings growth. Upon studying the latest analysts' consensus data, we found that the company is expected to keep paying out approximately 48% of its profits over the next three years. Regardless, the future ROE for Siemens Healthineers is predicted to rise to 16% despite there being not much change expected in its payout ratio.

Conclusion

In total, we are pretty happy with Siemens Healthineers' performance. We are particularly impressed by the considerable earnings growth posted by the company, which was likely backed by its high ROE. While the company is paying out most of its earnings as dividends, it has been able to grow its earnings in spite of it, so that's probably a good sign. With that said, the latest industry analyst forecasts reveal that the company's earnings are expected to accelerate. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments
09.02.25 06:31:39 Siemens Healthineers AG (ETR:SHL) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Siemens Healthineers AG (ETR:SHL) just released its first-quarter report and things are looking bullish. Results were good overall, with revenues beating analyst predictions by 2.1% to hit €5.5b. Statutory earnings per share (EPS) came in at €0.42, some 4.3% above whatthe analysts had expected. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.

See our latest analysis for Siemens Healthineers XTRA:SHL Earnings and Revenue Growth February 9th 2025

Taking into account the latest results, the consensus forecast from Siemens Healthineers' 17 analysts is for revenues of €23.8b in 2025. This reflects a modest 5.0% improvement in revenue compared to the last 12 months. Per-share earnings are expected to leap 20% to €2.13. Yet prior to the latest earnings, the analysts had been anticipated revenues of €23.7b and earnings per share (EPS) of €2.12 in 2025. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at €61.60. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Siemens Healthineers analyst has a price target of €69.10 per share, while the most pessimistic values it at €49.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We would highlight that Siemens Healthineers' revenue growth is expected to slow, with the forecast 6.7% annualised growth rate until the end of 2025 being well below the historical 10.0% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 5.9% annually. So it's pretty clear that, while Siemens Healthineers' revenue growth is expected to slow, it's expected to grow roughly in line with the industry.

Story Continues

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

With that in mind, we wouldn't be too quick to come to a conclusion on Siemens Healthineers. Long-term earnings power is much more important than next year's profits. We have estimates - from multiple Siemens Healthineers analysts - going out to 2027, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 1 warning sign for Siemens Healthineers that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments
06.02.25 09:16:00 Siemens Healthineers Profit, Sales Beat Market Views
The healthcare-equipment company posted net profit of 474 million euros for its first fiscal quarter, topping analysts’ expectations.

Continue Reading

View Comments
30.01.25 05:44:27 Is Siemens Healthineers AG (ETR:SHL) Trading At A 44% Discount?
Key Insights

Siemens Healthineers' estimated fair value is €97.80 based on 2 Stage Free Cash Flow to Equity Siemens Healthineers is estimated to be 44% undervalued based on current share price of €54.58 Analyst price target for SHL is €60.04 which is 39% below our fair value estimate

Does the January share price for Siemens Healthineers AG (ETR:SHL) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to today's value. This will be done using the Discounted Cash Flow (DCF) model. Before you think you won't be able to understand it, just read on! It's actually much less complex than you'd imagine.

We would caution that there are many ways of valuing a company and, like the DCF, each technique has advantages and disadvantages in certain scenarios. Anyone interested in learning a bit more about intrinsic value should have a read of the Simply Wall St analysis model.

View our latest analysis for Siemens Healthineers

The Calculation

We are going to use a two-stage DCF model, which, as the name states, takes into account two stages of growth. The first stage is generally a higher growth period which levels off heading towards the terminal value, captured in the second 'steady growth' period. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, and so the sum of these future cash flows is then discounted to today's value:

10-year free cash flow (FCF) forecast

2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 Levered FCF (€, Millions) €2.77b €2.91b €3.41b €4.18b €4.57b €4.85b €5.07b €5.25b €5.39b €5.50b Growth Rate Estimate Source Analyst x7 Analyst x7 Analyst x3 Analyst x1 Analyst x1 Est @ 6.06% Est @ 4.53% Est @ 3.46% Est @ 2.71% Est @ 2.18% Present Value (€, Millions) Discounted @ 5.3% €2.6k €2.6k €2.9k €3.4k €3.5k €3.6k €3.5k €3.5k €3.4k €3.3k

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = €32b

Story Continues

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. The Gordon Growth formula is used to calculate Terminal Value at a future annual growth rate equal to the 5-year average of the 10-year government bond yield of 1.0%. We discount the terminal cash flows to today's value at a cost of equity of 5.3%.

Terminal Value (TV)= FCF2034 × (1 + g) ÷ (r – g) = €5.5b× (1 + 1.0%) ÷ (5.3%– 1.0%) = €129b

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €129b÷ ( 1 + 5.3%)10= €77b

The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is €109b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of €54.6, the company appears quite good value at a 44% discount to where the stock price trades currently. The assumptions in any calculation have a big impact on the valuation, so it is better to view this as a rough estimate, not precise down to the last cent.XTRA:SHL Discounted Cash Flow January 30th 2025

The Assumptions

The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Siemens Healthineers as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 5.3%, which is based on a levered beta of 1.047. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

SWOT Analysis for Siemens Healthineers

Strength

Earnings growth over the past year exceeded the industry.

Debt is well covered by earnings.

Dividends are covered by earnings and cash flows.

Weakness

Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.

Opportunity

Annual revenue is forecast to grow faster than the German market.

Good value based on P/E ratio and estimated fair value.

Threat

Debt is not well covered by operating cash flow.

Annual earnings are forecast to grow slower than the German market.

Looking Ahead:

Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Instead the best use for a DCF model is to test certain assumptions and theories to see if they would lead to the company being undervalued or overvalued. For example, changes in the company's cost of equity or the risk free rate can significantly impact the valuation. Can we work out why the company is trading at a discount to intrinsic value? For Siemens Healthineers, there are three important items you should consider:

Risks: Case in point, we've spotted 1 warning sign for Siemens Healthineers you should be aware of. Future Earnings: How does SHL's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other Solid Businesses: Low debt, high returns on equity and good past performance are fundamental to a strong business. Why not explore our interactive list of stocks with solid business fundamentals to see if there are other companies you may not have considered!

PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the XTRA every day. If you want to find the calculation for other stocks just search here.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Comments
06.11.24 06:38:00 Siemens Healthineers Net Profit, Revenue Miss Views
The German healthcare company posted lower-than-expected net profit and revenue, despite a rise in sales.

Continue reading

View comments